Site-Directed Engineering of Defined Chromosomal Sites for Recombinant Protein and Virus Expression - Site-directed engineering of defined chromosomal sites. - BioPharm International


Site-Directed Engineering of Defined Chromosomal Sites for Recombinant Protein and Virus Expression
Site-directed engineering of defined chromosomal sites.

BioPharm International
Volume 22, Issue 7


1. Bell AC, Felsenfeld G. Stopped at the border: boundaries and insulators. Curr Opin Genet Dev. 1999 Apr;9(2):191–8.

2. Festenstein R, Tolaini M, Corbella P, et al. Locus control region function and heterochromatin-induced position effect variegation. Science. 1996 Feb 23;271(5252):1123–5.

3. Schucht R, Coroadinha AS, Zanta-Boussif MA, et al. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. Mol Ther. 2006 Aug;14(2):285–92.

4. Coroadinha AS, Schucht R, Gama-Norton L, Wirth D, Hauser H, Carrondo MJ. The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange. J Biotechnol. 2006 Jul 13;124(2):457–68.

5. Yarranton GT. Mammalian recombinant proteins: vectors and expression systems. Curr Opin Biotechnol. 1990 Dec;1(2):133–40.

6. Gama-Norton LR, P.; Sandhu U, Nehlsen K.; Schucht R, Hauser H, Wirth D. Defeating randomness—Targeted Integration as a Boost for Biotechnology. In: M. Al-Rubeai E, ed. Cell Engineering; in press.

7. Wirth D, Gama-Norton L, Riemer P, Sandhu U, Schucht R, Hauser H. Road to precision: recombinase-based targeting technologies for genome engineering. Curr Opin Biotechnol. 2007 Sep 26.

8. Baer A, Bode J. Coping with kinetic and thermodynamic barriers: RMCE, an efficient strategy for the targeted integration of transgenes. Curr Opin Biotechnol. 2001 Oct;12(5):473–80.

9. Hauser H, Spitzer D, Verhoeyen E, Unsinger J, Wirth D. New approaches towards ex vivo and in vivo gene therapy. Cells Tissues Organs. 2000;167(2-3):75–80.

10. Verhoeyen E, Hauser H, Wirth D. Evaluation of retroviral vector design in defined chromosomal loci by Flp-mediated cassette replacement. Hum Gene Ther. 2001 May 20;12(8):933–44.

11. Nehlsen K, Schucht R, Gama-Norton L, Krömer W, Baer A, Cayli A, Hauser H, Wirth, D. Recombinant protein expression by targeting pre-selected chromosomal loci. Submitted.

12. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007–an update. J Gene Med. 2007 Oct;9(10):833–42.

13. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000 Apr 28;288(5466):669–72.

14. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. Apr 2006;12(4):401–9.

15. Fischer A, Cavazzana-Calvo M. Gene therapy of inherited diseases. Lancet. Jun 14 2008;371(9629):2044–7.

16. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 1993;217:581–99.

17. Gama-Norton L, Herrmann S, Schucht R, Coroadinha A, Löw R, Alves P, Baum C, Schambach A, Hauser H, Wirth D. Retroviral vector performance upon integration in to defined chromosomal loci of modular packaging cell lines. Submitted.

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here